BR122012014331A2 - - Google Patents

Info

Publication number
BR122012014331A2
BR122012014331A2 BR122012014331A BR122012014331A BR122012014331A2 BR 122012014331 A2 BR122012014331 A2 BR 122012014331A2 BR 122012014331 A BR122012014331 A BR 122012014331A BR 122012014331 A BR122012014331 A BR 122012014331A BR 122012014331 A2 BR122012014331 A2 BR 122012014331A2
Authority
BR
Brazil
Application number
BR122012014331A
Other languages
Portuguese (pt)
Other versions
BR122012014331B8 (pt
BR122012014331A8 (pt
BR122012014331B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10780813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122012014331(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR122012014331A2 publication Critical patent/BR122012014331A2/pt
Publication of BR122012014331A8 publication Critical patent/BR122012014331A8/pt
Publication of BR122012014331B1 publication Critical patent/BR122012014331B1/pt
Publication of BR122012014331B8 publication Critical patent/BR122012014331B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR122012014331A 1995-09-15 1996-08-21 formulações farmacêuticas BR122012014331B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9518953.6A GB9518953D0 (en) 1995-09-15 1995-09-15 Pharmaceutical formulations
GB9518953.6 1995-09-15
PCT/EP1996/003719 WO1997009980A1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin
BRPI9610153 1996-08-21

Publications (4)

Publication Number Publication Date
BR122012014331A2 true BR122012014331A2 (en:Method) 1999-01-05
BR122012014331A8 BR122012014331A8 (pt) 2018-07-31
BR122012014331B1 BR122012014331B1 (pt) 2019-10-08
BR122012014331B8 BR122012014331B8 (pt) 2021-05-25

Family

ID=10780813

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122012014331A BR122012014331B8 (pt) 1995-09-15 1996-08-21 formulações farmacêuticas
BR9610153A BR9610153A (pt) 1995-09-15 1996-08-21 Formulações farmacêuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9610153A BR9610153A (pt) 1995-09-15 1996-08-21 Formulações farmacêuticas

Country Status (32)

Country Link
US (1) US6106864A (en:Method)
EP (2) EP0850059B1 (en:Method)
JP (1) JP3403203B2 (en:Method)
KR (1) KR100348585B1 (en:Method)
CN (1) CN1303998C (en:Method)
AR (1) AR005231A1 (en:Method)
AT (2) ATE233090T1 (en:Method)
BR (2) BR122012014331B8 (en:Method)
CA (1) CA2230314C (en:Method)
CO (1) CO4750822A1 (en:Method)
CY (3) CY2468B1 (en:Method)
CZ (1) CZ294024B6 (en:Method)
DE (4) DE122005000024I2 (en:Method)
DK (2) DK0850059T3 (en:Method)
EG (1) EG23826A (en:Method)
ES (2) ES2224002T3 (en:Method)
FR (1) FR05C0019I2 (en:Method)
GB (1) GB9518953D0 (en:Method)
HU (2) HU225236B1 (en:Method)
IL (1) IL122746A (en:Method)
LU (1) LU91163I2 (en:Method)
MY (1) MY125662A (en:Method)
NL (1) NL300190I2 (en:Method)
NO (2) NO314783B1 (en:Method)
NZ (1) NZ316924A (en:Method)
PL (1) PL185604B1 (en:Method)
PT (1) PT1245231E (en:Method)
RU (1) RU2163803C2 (en:Method)
TR (1) TR199800461T1 (en:Method)
TW (1) TW442300B (en:Method)
WO (1) WO1997009980A1 (en:Method)
ZA (1) ZA967745B (en:Method)

Families Citing this family (309)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011888A1 (en) * 1996-09-19 1998-03-26 American Home Products Corporation Method of treating urinary incontinence
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US7858119B1 (en) * 2000-05-09 2010-12-28 Amina Odidi Extended release pharmaceuticals
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
GB0129962D0 (en) 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
WO2004096810A1 (en) 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
ATE539077T1 (de) * 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
EP1682545B1 (en) * 2003-10-03 2007-12-12 Pfizer Limited Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0402491D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Medicaments
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
EP1735284A1 (en) * 2004-03-18 2006-12-27 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
US7538141B2 (en) * 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
US20050215542A1 (en) * 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
AP2315A (en) * 2004-03-23 2011-11-04 Pfizer Formamide derivatives useful as adrenoceptor.
CA2562251C (en) * 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA200801608A1 (ru) * 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
ES2314690T3 (es) * 2004-08-12 2009-03-16 Pfizer, Inc. Derivados de triazolopiridinilsulfanilo como inhibidores de la map quinasa p38.
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN101023064B (zh) 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
GEP20094845B (en) * 2004-08-26 2009-11-25 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
DE602005011844D1 (de) * 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
US20060111416A1 (en) * 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
JP4521463B2 (ja) 2005-03-17 2010-08-11 ファイザー株式会社 疼痛の治療に有用なｎ−（ｎ−スルホニルアミノメチル）シクロプロパンカルボキサミド誘導体
EP1866278A1 (en) * 2005-03-28 2007-12-19 Pfizer, Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US20070149464A1 (en) * 2005-06-15 2007-06-28 Pfizer Inc. Combination
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
AU2006257647A1 (en) * 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasites
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) * 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
WO2007027675A1 (en) 2005-09-02 2007-03-08 Theravida, Inc Therapy for the treatment of disease
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
BRPI0711358A2 (pt) 2006-05-09 2011-09-27 Pfizer Prod Inc derivados do ácido cicloalquilamino e suas composições farmacêuticas
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008017932A2 (en) * 2006-08-09 2008-02-14 Pfizer Products Inc. Heterocycles useful as inhibitors of carbonic anhydrase
CA2664251A1 (en) * 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
ATE512969T1 (de) * 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
US8158650B2 (en) 2006-10-23 2012-04-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
RU2322998C1 (ru) * 2006-11-16 2008-04-27 Общество с ограниченной ответственностью "Березовый мир" Носитель лекарственных и диагностических средств
AP2455A (en) 2007-02-02 2012-08-31 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
US20100216823A1 (en) * 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
US20110092564A1 (en) * 2008-02-26 2011-04-21 Ernest Puil Cyclic amino acids for the treatment of pain
WO2009140078A1 (en) * 2008-05-16 2009-11-19 The Procter & Gamble Company Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
BRPI0912679A2 (pt) * 2008-05-16 2016-01-26 Axis Inc composição farmacêutica para o tratamento de fibromialgia
ES2465478T3 (es) * 2008-05-30 2014-06-05 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden brivaracetam
US8518952B2 (en) * 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
KR101637337B1 (ko) 2008-11-21 2016-07-07 라퀄리아 파마 인코포레이티드 5-ｈｔ2ｂ 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
PT2385938E (pt) 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
US8828937B2 (en) 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2236516A1 (en) 2009-03-31 2010-10-06 Charité-Universitätsmedizin Berlin (Charité) Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
US8617763B2 (en) * 2009-08-12 2013-12-31 Bloom Energy Corporation Internal reforming anode for solid oxide fuel cells
MX2012006490A (es) 2009-12-11 2012-07-03 Du Pont Inhibidores azociclicos de hidrolasa de amidas de acidos grasos.
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
ME02186B (me) 2009-12-23 2016-02-20 Takeda Pharmaceuticals Co Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
JP2013525476A (ja) 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
CA2804173C (en) 2010-07-09 2015-01-13 Pfizer Limited Sulfonamide nav1.7 inhibitors
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
AU2011330850B2 (en) 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2678342B1 (en) 2011-02-25 2015-01-07 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
EA201391239A1 (ru) 2011-04-05 2014-03-31 Пфайзер Лимитед Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
WO2012154775A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
CA2836372C (en) 2011-05-18 2020-09-22 Raqualia Pharma Inc. Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013017989A1 (en) 2011-08-02 2013-02-07 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
WO2013057624A1 (en) 2011-10-19 2013-04-25 Ah Usa 42 Llc Use of aminoacetonitrile derivatives against endoparasites
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
EP2771335A2 (en) 2011-10-26 2014-09-03 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
ES2648901T3 (es) 2011-10-28 2018-01-08 Inhibitaxin Limited Derivados de piridazina útiles en terapia
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CN102579379B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种药物缓释制剂及其制备方法
CN102600096B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种达非那新缓释制剂及其制备方法
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
CN104203242B (zh) 2012-04-04 2017-03-15 杭州德润玉成生物科技有限公司 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
JP6463680B2 (ja) 2012-09-18 2019-02-06 ジアルコ ファーマ リミテッドＺｉａｒｃｏ Ｐｈａｒｍａ Ｌｔｄ 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
UA111687C2 (uk) 2012-11-08 2016-05-25 Пфайзер Інк. Гетероароматичні сполуки як ліганди допаміну d1
EP3323821A1 (en) 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
WO2014080633A1 (en) 2012-11-21 2014-05-30 Raqualia Pharma Inc. Polymorph forms
AU2013353723B2 (en) 2012-12-03 2018-02-22 Pfizer Inc. Novel selective androgen receptor modulators
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
ES2694787T3 (es) 2013-02-21 2018-12-27 Pfizer Inc. Formas sólidas de un inhibidor selectivo de CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US20160022661A1 (en) * 2013-03-13 2016-01-28 Ratiopharm Gmbh Dosage Form Comprising Crizotinib
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
US9603934B2 (en) 2013-05-17 2017-03-28 Acupac Packaging, Inc. Anhydrous hydrogel composition and delivery system
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
CN106232118A (zh) 2014-04-25 2016-12-14 辉瑞大药厂 杂芳族化合物及其作为多巴胺d1配体的用途
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3134404A1 (en) 2014-04-25 2017-03-01 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
JP6564394B2 (ja) 2014-04-28 2019-08-21 ファイザー・インク 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
SG11201609139WA (en) 2014-05-14 2016-11-29 Pfizer Pyrazolopyridines and pyrazolopyrimidines
SG11201608320QA (en) 2014-05-15 2016-11-29 Pfizer Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
TWI672300B (zh) 2014-05-20 2019-09-21 日商拉夸里亞創藥股份有限公司 苯并異唑衍生物鹽類
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
WO2015181797A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
DK3157915T3 (en) 2014-06-17 2019-04-23 Pfizer Substituted dihydroisoquinolinone compounds
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
US9765000B2 (en) 2015-01-22 2017-09-19 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
CU20170105A7 (es) 2015-02-24 2017-10-05 Pfizer Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
US10214509B2 (en) 2015-04-21 2019-02-26 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
PE20180395A1 (es) 2015-06-04 2018-02-28 Pfizer Formas de dosificacion solidas de palbociclib
DK3328849T5 (da) 2015-07-31 2021-02-15 Pfizer 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CA3007595C (en) 2015-12-10 2020-08-25 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
KR102687603B1 (ko) 2015-12-24 2024-07-24 다케다 야쿠힌 고교 가부시키가이샤 공결정, 이의 제조방법 및 공결정을 함유하는 의약
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
US10590128B2 (en) 2016-01-15 2020-03-17 Pfizer, Inc. 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
KR102495757B1 (ko) 2016-01-20 2023-02-06 테라비다, 인코포레이티드 다한증을 치료하기 위한 방법 및 조성물
EP3426772A4 (en) 2016-03-09 2019-08-28 Beijing Percans Oncology Co. Ltd. TUMOR CELLSUSPENSION CULTURES AND RELATED METHODS
PL3436447T3 (pl) 2016-03-31 2021-12-27 Takeda Pharmaceutical Company Limited Kompleksy triazolonu izochinolinylowego
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
CA3033667A1 (en) 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
PT3497103T (pt) 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
WO2018118791A2 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
US11306075B2 (en) 2016-12-20 2022-04-19 Oligomerix, Inc. Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
EP3571191A1 (en) 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
MX2019008773A (es) 2017-01-24 2019-09-18 Pfizer Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
JP7142675B2 (ja) 2017-03-26 2022-09-27 武田薬品工業株式会社 Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
WO2018234808A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
JP7311514B2 (ja) 2017-08-30 2023-07-19 ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
CA3082287C (en) 2017-11-14 2023-02-28 Pfizer Inc. Ezh2 inhibitor combination therapies
AU2019211188A1 (en) 2018-01-29 2020-07-30 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
US20200405809A1 (en) 2018-02-27 2020-12-31 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
EP3823723A1 (en) 2018-07-19 2021-05-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CN113330015A (zh) 2019-01-23 2021-08-31 辉瑞大药厂 已知四氢异喹啉衍生物的单磷酸盐水合物盐的多晶型物形式
AU2020213761C1 (en) 2019-01-31 2023-08-10 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
AU2020228047A1 (en) 2019-02-27 2021-09-30 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
TW202102498A (zh) 2019-03-22 2021-01-16 日商武田藥品工業股份有限公司 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
PE20220425A1 (es) 2019-04-29 2022-03-29 Solent Therapeutics Llc Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
WO2021014415A2 (en) 2019-07-25 2021-01-28 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
CN114728975A (zh) 2019-09-16 2022-07-08 武田药品工业株式会社 唑稠合的哒嗪-3(2h)-酮衍生物
KR20220141328A (ko) 2020-02-12 2022-10-19 큐라데브 파마 프라이버트 리미티드 소분자 sting 길항제
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
EP4132925A1 (en) 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
WO2021220185A1 (en) 2020-05-01 2021-11-04 Pfizer Inc. Azalactam compounds as hpk1 inhibitors
CN115515933A (zh) 2020-05-04 2022-12-23 武田药品工业株式会社 经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2021239863A1 (en) 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
MX2022015254A (es) 2020-06-04 2023-01-11 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de peptidasa especifica de ubiquitina 30.
AU2021286831A1 (en) 2020-06-08 2023-02-02 Mission Therapeutics Limited 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4- methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
WO2022013691A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
US20240000783A1 (en) 2020-08-13 2024-01-04 Pfizer Inc. Combination therapy
AU2021345531B2 (en) 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
JP7706558B2 (ja) 2020-10-09 2025-07-11 ナパ，セラピューティクス・リミテッド Ｃｄ３８のヘテロアリールアミド阻害剤
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
CA3206158A1 (en) 2020-12-22 2022-06-30 Effector Therapeutics, Inc. Solid forms of an eif4e inhibitor
CA3206153A1 (en) 2020-12-24 2022-06-30 Pfizer Inc. Solid forms of a cdk2 inhibitor
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
AU2022244439A1 (en) 2021-03-24 2023-09-28 Astellas Pharma Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
CA3213593A1 (en) 2021-03-31 2022-10-06 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
EP4320121A2 (en) 2021-04-07 2024-02-14 LifeArc 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
WO2022229846A1 (en) 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
WO2022269531A1 (en) 2021-06-26 2022-12-29 Array Biopharma Inc. Her2 mutation inhibitors
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
CN118019738A (zh) 2021-08-11 2024-05-10 库拉德夫制药私人有限公司 作为sting拮抗剂的小分子脲衍生物
IL310705A (en) 2021-08-11 2024-04-01 Curadev Pharma Pvt Ltd Small molecule STING antagonists
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
US20250042918A1 (en) 2021-12-01 2025-02-06 Fundación Del Sector Públlco Estatal Centro Nacional De Investigaciones Oncológicas Carlos III Compounds
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
WO2023100134A1 (en) 2021-12-02 2023-06-08 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
KR20240169050A (ko) 2022-03-30 2024-12-02 다케다 야쿠힌 고교 가부시키가이샤 N-(피롤리딘-3-일 또는 피페리딘-4-일)아세트아마이드 유도체
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
EP4554674A1 (en) 2022-07-15 2025-05-21 Jazz Pharmaceuticals Ireland Limited Biaryl ether urea compounds as faah inhibitors
MA71611A (fr) 2022-07-29 2025-05-30 Pfizer Inc. Nouveaux inhibiteurs de l'acc
AR130151A1 (es) 2022-08-10 2024-11-06 Takeda Pharmaceuticals Co Compuesto heterocíclico
JP2025526784A (ja) 2022-08-11 2025-08-15 イヴクスタ・バイオ 癌を処置するための化合物
EP4598538A1 (en) 2022-10-05 2025-08-13 Sevenless Therapeutics Limited New treatments for pain
WO2024105363A1 (en) 2022-11-15 2024-05-23 Curadev Pharma Ltd Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
AU2024208288A1 (en) 2023-01-13 2025-07-03 Neurim Pharmaceuticals (1991) Ltd. Piromelatine for treating parasomnias associated with loss of rem sleep atonia
WO2024157205A1 (en) 2023-01-26 2024-08-02 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
TW202506678A (zh) 2023-04-14 2025-02-16 日商武田藥品工業股份有限公司 雜環化合物
WO2024251978A1 (en) 2023-06-09 2024-12-12 Institut Gustave Roussy Drug conjugate targeting ctla4, products comprising the same and therapeutic uses thereof
TW202500155A (zh) 2023-06-12 2025-01-01 美商亞文納營運公司 雌激素受體降解劑之固體口服劑型
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
US20250057848A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
CZ294024B6 (cs) 2004-09-15
KR19990044653A (ko) 1999-06-25
NO981073D0 (no) 1998-03-11
CY2468B1 (en) 2005-06-03
ZA967745B (en) 1998-03-13
HU227397B1 (en) 2011-05-30
TR199800461T1 (xx) 1998-05-21
CO4750822A1 (es) 1999-03-31
HU0500976D0 (en) 2005-12-28
HU225236B1 (en) 2006-08-28
DE122005000024I1 (de) 2005-08-04
HUP9802339A2 (hu) 1999-08-30
CY2005007I2 (el) 2009-11-04
CY2005007I1 (el) 2009-11-04
NZ316924A (en) 1999-06-29
EP1245231A3 (en) 2003-01-15
ES2224002T3 (es) 2005-03-01
HUP9802339A3 (en) 1999-09-28
BR122012014331B8 (pt) 2021-05-25
CA2230314A1 (en) 1997-03-20
MY125662A (en) 2006-08-30
KR100348585B1 (ko) 2002-10-31
CA2230314C (en) 2003-06-24
BR122012014331A8 (pt) 2018-07-31
DK0850059T3 (da) 2003-03-31
DE69626397D1 (de) 2003-04-03
MX9802026A (es) 1998-08-30
NL300190I1 (nl) 2005-07-01
PL325598A1 (en) 1998-08-03
JPH10511112A (ja) 1998-10-27
NO2005009I1 (no) 2005-04-18
EP1245231B1 (en) 2004-06-16
NO2005009I2 (no) 2006-11-27
IL122746A (en) 2000-12-06
DE69632753D1 (de) 2004-07-22
CZ73298A3 (cs) 1999-03-17
LU91163I2 (fr) 2005-06-20
NL300190I2 (nl) 2005-08-01
NO314783B1 (no) 2003-05-26
DE122005000024I2 (de) 2006-11-23
JP3403203B2 (ja) 2003-05-06
AR005231A1 (es) 1999-04-28
AU6927596A (en) 1997-04-01
CY2585B2 (en) 2009-11-04
DK1245231T3 (da) 2004-10-25
PL185604B1 (pl) 2003-06-30
GB9518953D0 (en) 1995-11-15
FR05C0019I2 (en:Method) 2005-11-04
WO1997009980A1 (en) 1997-03-20
EG23826A (en) 2007-09-25
ATE233090T1 (de) 2003-03-15
DE69632753T2 (de) 2005-07-14
BR122012014331B1 (pt) 2019-10-08
TW442300B (en) 2001-06-23
FR05C0019I1 (en:Method) 2005-05-27
PT1245231E (pt) 2004-10-29
RU2163803C2 (ru) 2001-03-10
AU703866B2 (en) 1999-04-01
NO981073L (no) 1998-03-11
CN1303998C (zh) 2007-03-14
EP1245231A2 (en) 2002-10-02
ATE269076T1 (de) 2004-07-15
ES2188782T3 (es) 2003-07-01
BR9610153A (pt) 1999-01-05
EP0850059A1 (en) 1998-07-01
IL122746A0 (en) 1998-08-16
EP0850059B1 (en) 2003-02-26
DE69626397T2 (de) 2003-07-17
CN1195984A (zh) 1998-10-14
US6106864A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
FR05C0019I1 (en:Method)
BRPI9612258B1 (en:Method)
BRPI9612138B1 (en:Method)
CH0741373H1 (en:Method)
BR7501503U (en:Method)
BR7502120U (en:Method)
BY5258C1 (en:Method)
CN3029801S (en:Method)
CN3029928S (en:Method)
CN3030154S (en:Method)
CN3030197S (en:Method)
CN3030225S (en:Method)
CN3030296S (en:Method)
CN3030415S (en:Method)
CN3030489S (en:Method)
CN3030542S (en:Method)
CN3030543S (en:Method)
CN3030760S (en:Method)
CN3031001S (en:Method)
CN3031350S (en:Method)
CN3031655S (en:Method)
CN3031742S (en:Method)
CN3031926S (en:Method)
CN3032332S (en:Method)
CN3032390S (en:Method)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A

Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO NO 860140144619, DE 27/08/2014, E NECESSARIO REGULARIZAR O NOME DO CEDENTE. PARA TANTO, DEVE-SE RECOLHER AS GUIAS DE ALTERACAO DE NOME E A REFERENTE A ESTA EXIGENCIA, E APRESENTAR DOCUMENTO COMPROBATORIO NOTARIZADO E CONSULARIZADO.

B25B Requested transfer of rights rejected

Owner name: PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE TRANSFERENCIA(S) CONTIDO(S) NA PETICAO NO 860140144619, DE 27/08/2014, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2290, DE 25/11/2014.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM)

B25A Requested transfer of rights approved

Owner name: ASPEN GLOBAL INCORPORATED (MR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.4 NA RPI NO 2535 DE 06/08/2019 POR TER SIDO INDEVIDA.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/1996, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 21/08/2016